No Association Between TP53 Codon 72 Polymorphism and Lymphoma Risk or Prognosis

Strategic Insights -

Recent research published in Leukemia Research has shed light on the relationship between the TP53 codon 72 polymorphism and the risk or prognosis of Hodgkin and non-Hodgkin lymphoma. A team of researchers from Charles University in Prague, Czech Republic, conducted a study involving 340 non-Hodgkin lymphoma patients, 298 Hodgkin lymphoma patients, and 749 controls to investigate the role of the R72P polymorphism in lymphoma development and prognosis. The study's findings indicate that there was no significant difference in the R72P frequency between lymphoma cases and controls, nor was there an association between the R72P polymorphism and the risk of lymphoma development or survival.

Key Takeaways:

  • The study, conducted by O. Havranek and colleagues from Charles University, involved 340 non-Hodgkin lymphoma patients, 298 Hodgkin lymphoma patients, and 749 controls to investigate the role of the TP53 codon 72 polymorphism in lymphoma development and prognosis.
  • The results showed that there was no significant difference in the R72P frequency between lymphoma cases and controls (p>0.05).
  • The researchers found no association between the R72P polymorphism and the risk of non-Hodgkin lymphoma (OR(ArgPro/ProPro)=0.9; 95% CI 0.7-1.2) or Hodgkin lymphoma development (OR(ArgPro/ProPro)=1.2; 95% CI 0.9-1.5).
  • The study's findings support the evidence that R72P is not a prognostic factor in Caucasian non-Hodgkin lymphoma patients.
  • The study's results also indicate the irrelevance of the R72P polymorphism for Hodgkin lymphoma development or prognosis.
  • The study did not find any association between the R72P polymorphism and survival in patients with non-Hodgkin lymphoma or Hodgkin lymphoma.
  • The researchers concluded that their results suggest that the TP53 codon 72 polymorphism is not associated with the risk or prognosis of Hodgkin and non-Hodgkin lymphoma.

Statistics:

  • 340 non-Hodgkin lymphoma patients were included in the study.
  • 298 Hodgkin lymphoma patients were included in the study.
  • 749 controls were included in the study.
  • The odds ratio (OR) for the R72P polymorphism in non-Hodgkin lymphoma development was 0.9 (95% CI 0.7-1.2).
  • The odds ratio (OR) for the R72P polymorphism in Hodgkin lymphoma development was 1.2 (95% CI 0.9-1.5).
  • The study's findings support the evidence that R72P is not a prognostic factor in Caucasian non-Hodgkin lymphoma patients.

Sources:

  • Havranek, O., et al. (2011). No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma. Leukemia Research, 35(8), 1117-1119.